-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Emicker ★ Invitation Letter2021 CSGCT Gene and Cell Therapy Medical Summit will be held in Shanghai ★ Online Sharing｜Sino-US dual reporting strategy and upstream process development strategy for gene therapy products November 26, 2021 / Emark News eMedClub News/--The 2021 American Society of Hematology Annual Meeting (ASH) is coming again.
This meeting is the 63rd session.
Drugs for the treatment of patients with relapsed/refractory lymphoma have once again become the focus, including bispecific antibodies.
The drug model is expected to bring multiple choices to patients and doctors
.
It is reported that Roche will announce the key clinical trial results of mosunetuzumab in the treatment of patients with relapsed/refractory follicular lymphoma on the 2021 ASH
.
These patients have received at least two pre-treatments, of which 78.
9% of patients developed resistance to anti-CD20 antibody therapy
.
mosunetuzumab is a bispecific antibody under development that can target CD20 on the surface of B cells and CD3 on the surface of T cells
.
This dual-targeting feature can activate and redirect patient T cells, contact and release cytotoxic proteins to B cells
.
The structure of mosunetuzumab is similar to human natural antibody, with two Fab segments
.
But unlike natural antibodies, one of the Fab targets CD20, while the other targets CD3
.
Currently, mosunetuzumab clinical research and development program is underway, its purpose is to explore the molecule as a single or combination therapy for patients with CD20-positive B-cell non-Hodgkin lymphoma (including follicular lymphoma, diffuse large B-cell lymphoma and other Blood cancer)
.
The results of the trial showed that in patients receiving mosunetuzumab monotherapy, the objective response rate (ORR) reached 78.
9%, and the complete response rate (CR) reached 57.
8%
.
And in different patient subtypes, mosunetuzumab showed consistent anti-cancer activity and good safety
.
In addition, the Mosunetuzumab combination treatment program has entered a phase III clinical study.
Considering that lenalidomide can enhance the activity of T cells and NK cells, Mosunetuzumab and lenalidomide may show synergistic activity.
Sexual, multi-center, randomized controlled trial (NCT04712097), see the figure below for more research information
.
CD20/CD3 double antibody racetrack fierce double antibody has become the research and development hotspot of major pharmaceutical companies, and the CD20/CD3 target competition is particularly fierce
.
The structure of the bispecific antibody targeting CD20 and CD3 makes the drug more binding to CD20 on the surface of B cells, induces rapid T cell activation, cytokine release, and lysis of target cells
.
At present, Roche has obvious advantages in the field of CD20 target double antibodies
.
In addition to Mosunetuzumab, another CD20xCD3 bispecific antibody from Roche called Glofitamab is even more special
.
The antibody has a 2:1 TCB structure, including 2 anti-CD20 Fab and 1 anti-CD3 Fab
.
The results of the data released at the 2021ASCO conference show that the dose of glofitamab single-agent therapy is escalated.
In the R/R NHL patients who have failed multi-line therapy, the initial total remission rate is higher than the previous data
.
REGN1979 is a CD20/CD3 bispecific monoclonal antibody developed by Regeneron, which is designed to trigger tumor killing effect by binding to B cell tumor protein (CD20) and immune system T cell receptor (CD3).
It was developed to treat non-Hodgkin lymphoma (NHL) such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)
.
Recommended reading: ASH 2020: Regeneron CD20/CD3 double antibody shows positive clinical data, with CAR-T cells as a potential competitorYimai Meng broke the news on June 10, 2020, AbbVie and Genmab announced Reached a cooperation to jointly develop Genmab’s three next-generation bispecific antibody products, including CD3/CD20 bi-antibody epcoritamab (currently undergoing clinical trials for B-cell non-Hodgkin’s lymphoma).
Recommended reading: Bi-antibody track layout fiery! AbbVie and Genmab announced that they have reached a potential cooperation of US$4 billion.
The XmAb13676 double antibody was developed by Xencor.
The Fab part of the antibody targets CD20, and the scFv part of the antibody targets CD3 for B-cell malignant tumors
.
On March 17, 2021, Jiahe Biologics submitted GB261 (an innovative CD3/C20 bispecific antibody) to the Australian Bellberry Clinical Research Ethics Committee for the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL) patients.
First human clinical trial application (FIH)
.
Recommended reading: Jiahe Biologics CD3/C20 dual antibody applied for clinical application in AustraliaYimai Meng broke the news on July 2, 2021, the clinical trial application of "EX103 injection" declared by Guangzhou Aisimai Biomedical Technology Co.
, Ltd.
was approved by the State Food and Drug Administration The Center for Drug Evaluation (CDE) gave implied permission, and the indication is CD20-positive non-Hodgkin’s lymphoma
.
Recommended reading: Ai Simie Bio-CD20/CD3 bi-antibody is approved for clinical use Yimai Meng broke the news that the CM355 bi-specific antibody was jointly developed by Connoa/Nuocheng Jianhua and built on its nTCE platform, which has been demonstrated in pre-clinical experiments Good anti-tumor activity
.
Although Chinese biotech companies started late in the field of bispecific antibodies, they have developed extremely rapidly.
They have created a batch of products that have entered clinical trials.
I believe that in the near future, we will increase our understanding of a variety of benign and malignant blood diseases.
, In order to better meet the unfinished needs of patients
.
This meeting is the 63rd session.
Drugs for the treatment of patients with relapsed/refractory lymphoma have once again become the focus, including bispecific antibodies.
The drug model is expected to bring multiple choices to patients and doctors
.
It is reported that Roche will announce the key clinical trial results of mosunetuzumab in the treatment of patients with relapsed/refractory follicular lymphoma on the 2021 ASH
.
These patients have received at least two pre-treatments, of which 78.
9% of patients developed resistance to anti-CD20 antibody therapy
.
mosunetuzumab is a bispecific antibody under development that can target CD20 on the surface of B cells and CD3 on the surface of T cells
.
This dual-targeting feature can activate and redirect patient T cells, contact and release cytotoxic proteins to B cells
.
The structure of mosunetuzumab is similar to human natural antibody, with two Fab segments
.
But unlike natural antibodies, one of the Fab targets CD20, while the other targets CD3
.
Currently, mosunetuzumab clinical research and development program is underway, its purpose is to explore the molecule as a single or combination therapy for patients with CD20-positive B-cell non-Hodgkin lymphoma (including follicular lymphoma, diffuse large B-cell lymphoma and other Blood cancer)
.
The results of the trial showed that in patients receiving mosunetuzumab monotherapy, the objective response rate (ORR) reached 78.
9%, and the complete response rate (CR) reached 57.
8%
.
And in different patient subtypes, mosunetuzumab showed consistent anti-cancer activity and good safety
.
In addition, the Mosunetuzumab combination treatment program has entered a phase III clinical study.
Considering that lenalidomide can enhance the activity of T cells and NK cells, Mosunetuzumab and lenalidomide may show synergistic activity.
Sexual, multi-center, randomized controlled trial (NCT04712097), see the figure below for more research information
.
CD20/CD3 double antibody racetrack fierce double antibody has become the research and development hotspot of major pharmaceutical companies, and the CD20/CD3 target competition is particularly fierce
.
The structure of the bispecific antibody targeting CD20 and CD3 makes the drug more binding to CD20 on the surface of B cells, induces rapid T cell activation, cytokine release, and lysis of target cells
.
At present, Roche has obvious advantages in the field of CD20 target double antibodies
.
In addition to Mosunetuzumab, another CD20xCD3 bispecific antibody from Roche called Glofitamab is even more special
.
The antibody has a 2:1 TCB structure, including 2 anti-CD20 Fab and 1 anti-CD3 Fab
.
The results of the data released at the 2021ASCO conference show that the dose of glofitamab single-agent therapy is escalated.
In the R/R NHL patients who have failed multi-line therapy, the initial total remission rate is higher than the previous data
.
REGN1979 is a CD20/CD3 bispecific monoclonal antibody developed by Regeneron, which is designed to trigger tumor killing effect by binding to B cell tumor protein (CD20) and immune system T cell receptor (CD3).
It was developed to treat non-Hodgkin lymphoma (NHL) such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)
.
Recommended reading: ASH 2020: Regeneron CD20/CD3 double antibody shows positive clinical data, with CAR-T cells as a potential competitorYimai Meng broke the news on June 10, 2020, AbbVie and Genmab announced Reached a cooperation to jointly develop Genmab’s three next-generation bispecific antibody products, including CD3/CD20 bi-antibody epcoritamab (currently undergoing clinical trials for B-cell non-Hodgkin’s lymphoma).
Recommended reading: Bi-antibody track layout fiery! AbbVie and Genmab announced that they have reached a potential cooperation of US$4 billion.
The XmAb13676 double antibody was developed by Xencor.
The Fab part of the antibody targets CD20, and the scFv part of the antibody targets CD3 for B-cell malignant tumors
.
On March 17, 2021, Jiahe Biologics submitted GB261 (an innovative CD3/C20 bispecific antibody) to the Australian Bellberry Clinical Research Ethics Committee for the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL) patients.
First human clinical trial application (FIH)
.
Recommended reading: Jiahe Biologics CD3/C20 dual antibody applied for clinical application in AustraliaYimai Meng broke the news on July 2, 2021, the clinical trial application of "EX103 injection" declared by Guangzhou Aisimai Biomedical Technology Co.
, Ltd.
was approved by the State Food and Drug Administration The Center for Drug Evaluation (CDE) gave implied permission, and the indication is CD20-positive non-Hodgkin’s lymphoma
.
Recommended reading: Ai Simie Bio-CD20/CD3 bi-antibody is approved for clinical use Yimai Meng broke the news that the CM355 bi-specific antibody was jointly developed by Connoa/Nuocheng Jianhua and built on its nTCE platform, which has been demonstrated in pre-clinical experiments Good anti-tumor activity
.
Although Chinese biotech companies started late in the field of bispecific antibodies, they have developed extremely rapidly.
They have created a batch of products that have entered clinical trials.
I believe that in the near future, we will increase our understanding of a variety of benign and malignant blood diseases.
, In order to better meet the unfinished needs of patients
.
